TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
7/5/17 12:11 | 7/1/17 | NVET | Nexvet Biopharma Plc | L2 | Health | Drug | Pharmaceutical Preparations | Heffernan Mark | L2 | O | CEO | M.d | 8 | 0.1250 | 0 | 61 | 21 | 353 | D | ||||||||||||||
7/1/16 20:20 | 7/1/16 | NVET | Nexvet Biopharma Plc | L2 | Health | Drug | Pharmaceutical Preparations | Heffernan Mark | L2 | O | CEO | M.d | 4 | 0.1250 | 0 | 30 | 11 | 293 | D | -5 | 28 | 43 | 60 | 13 | 3 | -2 | 3 | 4 | 11 | -13 | -24 | ||
11/24/15 15:12 | 11/23/15 | NVET | Nexvet Biopharma Plc | L2 | Health | Drug | Pharmaceutical Preparations | Heffernan Mark | L2 | O | CEO | M.d | 1 | 0.1250 | 0 | 7 | 3 | 263 | D | -14 | -17 | 9 | -12 | -17 | 4 | -1 | -7 | -7 | -20 | -28 | 0 | ||
11/20/15 13:10 | 11/20/15 | NVET | Nexvet Biopharma Plc | L2 | Health | Drug | Pharmaceutical Preparations | Heffernan Mark | L2 | O | CEO | M.d | 1 | 0.1250 | 0 | 9 | 4 | 256 | I | -36 | -25 | 3 | -14 | -21 | -9 | 0 | 8 | -1 | -21 | -25 | 9 |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |